AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31286260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft with 10% collagen and collagen membrane
Number of subjects: 40
Study 31286260 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived xenograft particles and collagen membrane
Number of subjects: 40
Study 31286260 — intervention group
Group type: COMPARATOR
Intervention: No grafting (spontaneous healing)
Number of subjects: 40
Study 30345658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages consisting of multiple-choice questions with links to online material
Number of subjects: 162
Study 30345658 — intervention group
Group type: COMPARATOR
Intervention: No text messages (control group)
Number of subjects: 162
Study 27815068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir plus raltegravir
Number of subjects: 211
Study 27815068 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir plus two or three N(t)RTIs
Number of subjects: 211
Study 25902844 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF with elevated short chain n‐3 PUFA plus fish oil capsules
Number of subjects: 60
Study 25902844 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF with elevated short chain n‐3 PUFA
Number of subjects: 60
Study 25902844 — intervention group
Group type: COMPARATOR
Intervention: Standard RUTF
Number of subjects: 60
Study 24209829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART for 40 weeks (ART-40W)
Number of subjects: 377
Study 24209829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART for 96 weeks (ART-96W)
Number of subjects: 377
Study 24209829 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (ART-Def)
Number of subjects: 377
Study 21227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ⁹‐THC (30 mg)
Number of subjects: 6
Study 21227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1 mg)
Number of subjects: 6
Study 21227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg)
Number of subjects: 6
Study 21227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1 mg) + Δ⁹‐THC (5 mg)
Number of subjects: 6
Study 21227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg) + Δ⁹‐THC (15 mg)
Number of subjects: 6
Study 21227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg) + Δ⁹‐THC (30 mg)
Number of subjects: 6
Study 21227600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 19938054 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 927
Study 19938054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 17898377 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 12
Study 17898377 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend (NCT) monitoring
Number of subjects: 12
Study 15149420 — intervention group
Group type: EXPERIMENTAL
Intervention: RA mapping
Number of subjects: 35
Study 15149420 — intervention group
Group type: EXPERIMENTAL
Intervention: LA mapping
Number of subjects: 35
Study 15149420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bachmann's bundle block
Number of subjects: 35
Study 11499328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 0
Study 11499328 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.1% gel microsponge
Number of subjects: 0
Study 11499328 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 0
Study 11499328 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel
Number of subjects: 0
Study 11499328 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel (once-daily)
Number of subjects: 0
Study 11499328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel (alternate-day)
Number of subjects: 0
Study 9630388 — intervention group
Group type: COMPARATOR
Intervention: Selenium-enriched yeast, sodium selenate, or selenium-enriched wheat (Trial I)
Number of subjects: 50
Study 9630388 — intervention group
Group type: COMPARATOR
Intervention: Selenium-enriched yeast, sodium selenate, or sodium selenite (Trial II)
Number of subjects: 50
Study 7836711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 30
Study 7836711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2856602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream 1%
Number of subjects: 138
Study 2856602 — intervention group
Group type: COMPARATOR
Intervention: Ciclopirox 1%-hydrocortisone acetate 1% cream
Number of subjects: 138
Study 31350213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 0
Study 31350213 — intervention group
Group type: COMPARATOR
Intervention: High-frequency repetitive transcranial magnetic stimulation (10 Hz rTMS)
Number of subjects: 0
Study 27889221 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (ET)
Number of subjects: 77
Study 27889221 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 77
Study 26112747 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration
Number of subjects: 0
Study 26112747 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-group membership
Number of subjects: 0
Study 23527506 — intervention group
Group type: EXPERIMENTAL
Intervention: Very brief (25-ms, masked) images of spiders
Number of subjects: 53
Study 23527506 — intervention group
Group type: COMPARATOR
Intervention: Clearly visible (125-ms, unmasked) images of spiders
Number of subjects: 53
Study 23527506 — intervention group
Group type: COMPARATOR
Intervention: Very brief images of flowers
Number of subjects: 53
Study 21872140 — intervention group
Group type: EXPERIMENTAL
Intervention: Management guided by daily noninvasive estimated LVEDP monitoring (Group I, open)
Number of subjects: 50
Study 21872140 — intervention group
Group type: COMPARATOR
Intervention: Management based on clinical assessment alone (Group II, blinded)
Number of subjects: 50
Study 19440075 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg
Number of subjects: 383
Study 19440075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 17684203 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phenol olive oil (400 ppm)
Number of subjects: 21
Study 17684203 — intervention group
Group type: COMPARATOR
Intervention: Low-phenol olive oil (80 ppm)
Number of subjects: 21
Study 15285208 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's therapeutic community (TC)
Number of subjects: 0
Study 15285208 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (C)
Number of subjects: 0
Study 11446524 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical pathway for treating CAP (implemented in 9 hospitals)
Number of subjects: 1743
Study 11446524 — intervention group
Group type: COMPARATOR
Intervention: Conventional management of CAP (continued in 10 hospitals)
Number of subjects: 1743
Study 9757151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9757151 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 12
Study 9757151 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 12
Study 9757151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 12
Study 7533030 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin Mesylate (1 to 2 mg and from 2 to 4 mg over 45 days)
Number of subjects: 20
Study 7533030 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin Mesylate
Number of subjects: 20
Study 3062532 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of donor corneal epithelium
Number of subjects: 232
Study 3062532 — intervention group
Group type: COMPARATOR
Intervention: No removal of donor corneal epithelium
Number of subjects: 232
Study 30044899 — intervention group
Group type: COMPARATOR
Intervention: Amenamevir 400 mg daily for 10 days with Midazolam 7.5 mg
Number of subjects: 0
Study 30044899 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine 100 mg twice daily for 5 days with Amenamevir 400 mg and 1200 mg single doses
Number of subjects: 0
Study 30044899 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir 600 mg with Amenamevir 400 mg and 1200 mg single doses
Number of subjects: 0
Study 26850023 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for adherence to anti-psychotic medication
Number of subjects: 0
Study 26850023 — intervention group
Group type: COMPARATOR
Intervention: Control group without financial incentives
Number of subjects: 0
Study 25916954 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time splint wear
Number of subjects: 83
Study 25916954 — intervention group
Group type: COMPARATOR
Intervention: As-desired splint wear
Number of subjects: 83
Study 22947249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose b240 (2 × 10^9 cells)
Number of subjects: 300
Study 22947249 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose b240 (2 × 10^10 cells)
Number of subjects: 300
Study 22947249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no b240)
Number of subjects: 300
Study 22947249 — intervention group
Group type: EXPERIMENTAL
Intervention: b240 (both doses)
Number of subjects: 300
Study 19952772 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN (self-monitoring minutes of MVPA)
Number of subjects: 18
Study 19952772 — intervention group
Group type: COMPARATOR
Intervention: STE (self-monitoring steps/day)
Number of subjects: 18
Study 18977971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor-implemented, violence prevention intervention (6-session problem-solving curriculum and 3 home visits with a health educator)
Number of subjects: 166
Study 18977971 — intervention group
Group type: COMPARATOR
Intervention: Comparison group received a list of community resources and 2 follow-up telephone calls
Number of subjects: 166
Study 16809416 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg or 500 mg, depending on body weight) three times a week for 12 months
Number of subjects: 82
Study 16809416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 12635974 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint attention training using behavior modification procedures
Number of subjects: 0
Study 10851674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery and radiation therapy
Number of subjects: 88
Study 10851674 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 88
Study 10851674 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 88
Study 9417560 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 40
Study 9417560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 40
Study 9417560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 40
Study 9417560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 40
Study 1535170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac 10 micrograms
Number of subjects: 20
Study 1535170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac 5 micrograms
Number of subjects: 20
Study 3924081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (Transiderm‐Nitro 5)
Number of subjects: 12
Study 3924081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31888575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecuador's Multiple Traffic Lights (MTL)
Number of subjects: 2105
Study 31888575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chile's Warning Labels (WL)
Number of subjects: 2105
Study 31888575 — intervention group
Group type: COMPARATOR
Intervention: Mexican Guideline Daily Allowances (GDA)
Number of subjects: 2105
Study 29734139 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based e-coach (e-coaching)
Number of subjects: 83
Study 29734139 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 83
Study 27213837 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (AT)
Number of subjects: 120
Study 24636793 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss surgery
Number of subjects: 27
Study 24636793 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 27
Study 22956219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacteol (2 capsules/day) for 4 weeks
Number of subjects: 22
Study 20417081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna oil supplementation
Number of subjects: 0
Study 20417081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 18408393 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐ICAM‐1 levels in children with malignant lymphoma
Number of subjects: 35
Study 18408393 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐ICAM‐1 levels in advanced stages and high-grade NHL
Number of subjects: 35
Study 18408393 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH levels in patients
Number of subjects: 35
Study 18408393 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐ICAM‐1 levels in HD
Number of subjects: 35
Study 18408393 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐ICAM‐1 levels in NHL patients
Number of subjects: 35
Study 18408393 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐ICAM‐1 levels in HD and NHL
Number of subjects: 35
Study 16080280 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfen Patch 140 mg diclofenac sodium (test preparation)
Number of subjects: 24
Study 16080280 — intervention group
Group type: COMPARATOR
Intervention: 180 mg diclofenac epolamine plaster (reference preparation)
Number of subjects: 24
Study 12695914 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol hyperhydration (1.2 g kg(‐1) body mass glycerol mixed with 21 ml kg(‐1) body mass flavoured water)
Number of subjects: 7
Study 12695914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavoured water of equal volume to the GLY trial)
Number of subjects: 7
Study 12695914 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol hyperhydration
Number of subjects: 7
Study 12695914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10590497 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0
Study 10590497 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 0
Study 8987192 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine immunization scheme and a booster dose at 15 months of age
Number of subjects: 125
Study 8987192 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐immunized children)
Number of subjects: 125
Study 8987192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immunized and non‐immunized)
Number of subjects: 125
Study 1521627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography (IOUS)
Number of subjects: 82
Study 3881710 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefotaxime
Number of subjects: 100
Study 3881710 — intervention group
Group type: COMPARATOR
Intervention: Triple-dose cefotaxime
Number of subjects: 100
Study 30321667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (initial bolus dose of 2500 μg cholecalciferol followed by 100 μg cholecalciferol/d)
Number of subjects: 65
Study 30321667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 65
Study 30321667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30241477 — intervention group
Group type: EXPERIMENTAL
Intervention: High amylose maize starch (HAMS) sports oral rehydration solution
Number of subjects: 27
Study 30241477 — intervention group
Group type: COMPARATOR
Intervention: Usual hydration practices (Control)
Number of subjects: 27
Study 26671306 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (R-PSE)
Number of subjects: 84
Study 26671306 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach (F-PSE)
Number of subjects: 84
Study 24588291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 1726
Study 24588291 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 1726
Study 24588291 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726
Study 24588291 — intervention group
Group type: COMPARATOR
Intervention: All modalities (CBT, TSF, MET)
Number of subjects: 1726
Study 22305377 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg valganciclovir
Number of subjects: 10
Study 22305377 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg valganciclovir
Number of subjects: 10
Study 22305377 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg intravenous ganciclovir
Number of subjects: 10
Study 22305377 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg valganciclovir twice daily
Number of subjects: 10
Study 20149971 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with three or more children
Number of subjects: 491
Study 20149971 — intervention group
Group type: EXPERIMENTAL
Intervention: Women not breastfeeding
Number of subjects: 491
Study 20149971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 491
Study 17567393 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16137822 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeediCath hydrophilic-coated catheter
Number of subjects: 123
Study 16137822 — intervention group
Group type: COMPARATOR
Intervention: Uncoated PVC catheter
Number of subjects: 123
Study 11392580 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg once a day for 8 weeks
Number of subjects: 52
Study 11392580 — intervention group
Group type: COMPARATOR
Intervention: placebo for 8 weeks
Number of subjects: 52
Study 9949676 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8064597 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (Feldene, 20 mg daily)
Number of subjects: 45
Study 8064597 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (Naprosyn, 1,000 mg daily)
Number of subjects: 45
Study 3497686 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-tube technique
Number of subjects: 102
Study 3497686 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 102
Study 30393122 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal divergent thinking training
Number of subjects: 0
Study 30393122 — intervention group
Group type: COMPARATOR
Intervention: Control group (time-delayed training)
Number of subjects: 0
Study 26779980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (Ultrapro)
Number of subjects: 950
Study 26779980 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (Prolene)
Number of subjects: 950
Study 24923656 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g mesalazine suppository
Number of subjects: 129
Study 24923656 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 129
Study 23232609 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care intervention for late-life depression
Number of subjects: 514
Study 21489229 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP training program (one-day program on EBP principles and techniques)
Number of subjects: 54
Study 21489229 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 54
Study 21489229 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP training program
Number of subjects: 54
Study 18830666 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 1084
Study 18830666 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy
Number of subjects: 1084
Study 18830666 — intervention group
Group type: COMPARATOR
Intervention: Degree of extranodal extension
Number of subjects: 1084
Study 18830666 — intervention group
Group type: COMPARATOR
Intervention: Tumor grade
Number of subjects: 1084
Study 18830666 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 1084
Study 16808181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasocket Covomycin D
Number of subjects: 19
Study 16808181 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medicated side)
Number of subjects: 19
Study 14558957 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (5-8 times daily)
Number of subjects: 101
Study 14558957 — intervention group
Group type: COMPARATOR
Intervention: Dobell's solution (5-8 times daily)
Number of subjects: 101
Study 10999838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH therapy (13 IU/m2 x day)
Number of subjects: 0
Study 10999838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10999838 — intervention group
Group type: EXPERIMENTAL
Intervention: GH receptor antagonist (B2036)
Number of subjects: 0
Study 9059138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine 2-3 g per day (n = 37)
Number of subjects: 79
Study 9059138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 79
Study 8448068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine sustained release (I-SRO) 5 mg AM
Number of subjects: 18
Study 8448068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine sustained release (I-SRO) 5 mg PM
Number of subjects: 18
Study 8448068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6828943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline and amphotericin B vaginal cream (Vagmycin; Squibb)
Number of subjects: 0
Study 6828943 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients (control group)
Number of subjects: 0
Study 30880040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Velocity Nasal Insufflation (HVNI)
Number of subjects: 42
Study 30880040 — intervention group
Group type: COMPARATOR
Intervention: Non-Invasive Positive-Pressure Ventilation (NIPPV)
Number of subjects: 42